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vascular cell survival, proliferation and invasion during 
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Angiogenesis is the mechanism by which new blood vessels 
are formed from pre-existing vessels; this is distinct from 
vasculogenesis, where vessels develop from mesodermal 
angioblast precursor cells [l]. The mechanism of angiogen- 
esis can generally be divided into three phases, as shown 
for tumor-induced angiogenesis in Figure 1. 
The formation of new blood vessels facilitates physiologi- 
cal processes of embryonic development, female reproduc- 
tion and wound healing [Z]. However, angiogenesis also 
has a critical role in various pathological conditions such as 
solid tumor formation, metastasis, childhood hemangiomas, 
macular degeneration, diabetic retinopathy, psoriasis and 
inflammation-related diseases such as rheumatoid arthritis, 
ulcerative colitis and osteoarthritis [Z]. In particular, the 
expansion of solid tumors beyond a minimal size is criti- 
cally dependent on the formation of new blood vessels to 
supply oxygen, nutrients and growth factors, but angiogen- 
esis is also crucial for the formation of metastases at sec- 
ondary sites [Z]. Accordingly, inhibitors of angiogenesis 
have been suggested as therapeutic tools in the treatment 
of cancer [Z]. The members of one group of angiogcnesis 
inhibitors that will soon be tested in clinical trials are 
antagonists of a, integrins. This group includes genetically 
engineered monoclonal antibodies, synthetic linear and 
cyclic peptides, as well as naturally occurring venoms. 
lntegrins in angiogenesis 
Integrins are a family of heterodimeric transmembrane 
adhesion receptors that mediate cell-extracellular matrix 
interactions, such as cell adhesion and migration, and in 
some cases cell-cell adhesion [3]. The integrins and their 
respective ligands are summarized in Table 1. 
Endothelial cells express several distinct integrins, allow- 
ing attachment to a wide spectrum of extracellular-matrix 
@CM) components including fibronectin, vitronectin, 
laminin, collagen types I and IV, von Willebrand factor, 
fibrinogen and denatured collagen. The functions of intc- 
grins in endothclial cell biology have been studied in 
various Gz a& and in a& models. 1n vitro, one of the 
laminin receptors, integrin IX&~, has been implicated in 
capillary tube formation [4], a model involving endothelial 
cell migration and differentiation [S,S]. Function-blocking 
antibodies against either CQ or p1 blocked tube formation, 
whereas antibodies against CX~ did not [4]. This is consis- 
tent with a previously proposed role for laminin in 
endothelial cell differentiation into capillary tubes [5,6]. 
Integrin-mediated signaling events in cndathelial cells 
have also b&n studied using immobilized anti-integrin 
antibodies as agonists. While both pi and a& integrins 
mediate increases in intracellular pH, only ‘~~0~ is capable 
of mediating calcium influx [7]. However, conflicting 
results have been presented regarding endothelial cell 
tube formation using functional blocking antibodies 
against integrin Q3, and CI,&, since both have been 
reported to enhance as well as block tube formation 
[&lo]. These confusing findings underscore the problems 
of excluaiveIy examining models of angiogenesis 8a vitro, 
as the results are not necessarily predictive of the effects 
on angiogenesis in viuo. 
In V&JO, knockout of the gene encoding the fibronectin 
receptor (Ye subunit resulted in multiple lethal defects in 
early embryonic development, including blood vessel for- 
mation, similar to what is observed in fibronlctin knock- 
outs (reviewed in [ll]). However, ‘Y$~ is the integrin’that 
has been studied most extensively during angiogenesis in 
viwo. Integrin IX,& is preferentially expressed on angio- 
genie blood vessels, and subsequent blockage of o,& 
function by antibody or peptide antagonists prevents 
blood vessel formation in the chick chorioallancoic mem- 
brane (CAM), quail embryo, rabbit cornea, mouse retina 
and in human skin transplanted onto SCID mice (mice 
with severe combined immunodeficiency) [12-l 7j. In fact, 
this blockage of angiogenesis also results in an inhibition 
of tumor growth of a&-negative human tumors in the 
chick embryo (by inhibiting chick angiogenesis), and in 
human skin transplants in SCID mice (by inhibiting 
human angiogenesis within the skin) [13,14]. Notably, 
function blocking of CY,,& during angiogenesis leads to 
apoptosis selectively in proliferating angiogenic vessels 
[13]. This suggests that integrin CX,& has a unique func- 
tion during angiogenesis, namely to provide specific sur- 
vival signals that will facilitate vascular cell proliferation. 
Inccgrin (Y,& can interact with a wide variety of ECM 
proteins (Table 1). We recently showed that integrin (Y& 
can -also bind directIy to matrix metalloproteinase-2 
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Figure 1 
Tumor-induced angiogenesis. Angiogenesis, the formation of new 
btood vessels from pre-existing vessels, can generally be divided 
into three phases, as exemplified by tumor-induced angiogenesis. 
First, angiogenic stimulators such as bFGF and VEGF are released 
from the tumor and/or inflammatory cells. These angiogenic signals 
trigger the protiferating and invading phase, characterized by 
vascular cell proliferation, secretion of proteolytic enzymes and 
extraceltular matrix (ECM) molecules as well as altered expression 
of adhesion molecules. The proteolytic enzymes act to degrade 
extracel!ular matrix proteins, which together with new synthesis of 
ECM molecules results in a remodeling of the extracellular 
microenvironment. This remodeling, together with the altered 
adhesive properties of the vascular cells, is criticat as it facilitates 
vascular cetl survival, proliferation and migration, resulting in a 
vascular invasion of the ECM and the tumor. Finally, the vascular 
sprouts begin to mature by forming differentiated luminal structures, 
and to fuse into loops, thereby facilitating blood circulation in the 
new vessels. 
(MMP-Z), thereby 1ocaIizing MMP-2 mediated matrix 
degradation capacity to the vascular cell surface during 
angiogenesis [18]. These observations may shed light on 
how integrins and proteases function in a coordinated 
manner to promote cell invasion during angiogenesis and 
other cellular invasion events. 
While antagonists of oVp3 can block tumor-induced angio- 
genesis, individuals suffering from a form of Glanzmann 
thrombobascheoia have apparently normal blood vessels, 
despite lacking the integrin p3 subunit [19]. It can be 
noted, however, that these patients arc severely compro- 
mised in their wound-repair function. People with this 
disorder may develop blood vessels in the absence of CY,& 
by an alternative mechanism using integrin (Y&, which 
-can potenciace a distinct pathway of angiogenesis [16]. 
Recent pharmacological and toxicological studies indicate 
that antagonists of c& and/or o& are well tolerated in 
different species, suggesting that these antagonists might 
be safe for therapeutical purposes. In fact, clinical trials will 
soon be started for evaluation of humanized monoclonal 
antibodies against integrin IX,& as an anti-angiogenic 
therapy for cancer. Other antagonists of OL$~ and u$~ that 
are of potential clinical use are various Arg-Gly-Asp 
(KGD)-containing snake venoms, linear RGD peptides, as 
well as other short peptide sequences discovered using 
phage display libraries [ZO,Zl]. In addition, antagonists 
with high affinity and specificity for o, integrins have been 
developed in the form of cyclic peptides, such as RGD-fV, 
where f is the n-form of phenylalanine [ZZ]. 
Celi adhesion and apoptosis 
Integrins not only participate in cell adhesion and cyto- 
skeletal re-organization events necessary for cell migra- 
tion, but also mediate transmembrane signaling from the 
ECM into the cell [23,24]. Integrin-induced signals include 
I-I+ exchange, Caz+ influx, tyrosine, serine and threonine 
phosphorylation events, as well as ahered phosphoinositide 
metabolism. In many cases, these signals have been linked 
to the regulation of gene expression and contribute to 
mechanisms such as proliferation, differentiation and cell 
survival. Recent studies have demonstrated that integrin- 
mediated cell adhesion can also prevent apoptosis, a form 
of programmed cell death [13,25-271. 
Apoptosis is an evolutionary conserved process by which 
cells actively commit suicide, and it is critical for tissue 
homeostasis and the regulation of development and 
disease [ZB]. Adhesion-dependent proliferation is tightly 
regulated in most non-transformed cells, so a rote for inte- 
grin-ECM interactions in regulating apoptosis is well 
suited. However, studies in distinct cell systems under 
different conditions also suggest a role for diverse inte- 
grins as mediators of cell survival, Thuds, the particular 
inregrin mediating cell survival might be cell type- and 
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Table 1 -I_ 
lntegrins and their ligands and/or counterreceptors 
Subunits Ligands and/or counter-receptors --~- 
I% 
P2 
I33 
P4 
B5 
Pe 
P7 
Pa 
Collagens, laminin 
Collagefls, laminin 
Fibronectin, laminin, collagens, epiligrin, entactin 
Fibronectin, VCAM-1 
Fibronectin, Ll-CAM, tenascin, invasin 
Laminin, merosin, kalinin, invasin 
taminin 
Tenascin, fibronectin, vitronectin 
Collagen type I, laminin, tenascin 
Vitronectin, fibronectin, osteopontin 
ICAM-1, ICAM-2, ICAM- 
ICAM-I, fibrinogen, factor X, C3b 
Fibrinogen, C3b 
Fibrinogen, fibronectin, vitronectin, van Willebrand 
factor 
Vitronectin, osteopontin, fibrinogen, von Willsbrand 
factor, fibronectin, denatured collagen types I, IV and 
Vl, bone sialoprotein, thrombospondin, PECAM-1, 
Ll -CAM, fibrillin-I, tenascin 
Laminin, kalinin 
Vitronectin, osteoponhn, fibronectin 
Fibronectin 
Fibronectin, VCAM-I, MadCAM- 
? 
Fibronectin, vitronectin 
Intogrins are a family of transmembrane heterodimeric adhesion recep- 
tors composed of one cy and one p subunit. As indicated above, some 
of the integrin subunits are capable of forming dimers with more than 
one corresponding subunit. The integrins mediate cell-extracellular 
matrix interactions and in some cases cell-cell interactions, and are 
capable of transmitting various signals into the cell [20,21 I. The table 
is an updated adaption from 131. 
condition-specific. This may in part be explained by rhe 
distinct roles of different extracellular matrix components. 
For example, provisional matrices, such as fibronectin, 
vitroncctin and fibrinogen, typically potentiace cell prolif- 
eration, whereas the basement membrane promotes cell 
cycle withdrawal and differentiation [29,30]. Therefore, 
attachment to different ECM components is mediated 
through specific integrins, that can generate distinct 
signals that contribute to cell survival in multiple ways, 
(Table 1). To this end, Boudreau and colleagues [31] 
recently demonstrated a relationship between the type of 
ECM interaction and the specific survival signals in 
mammary cells. Differentiation of mammary epithelial 
cells was induced by interaction with a three-dimensional 
basement membrane type matrix and accompanied by 
down-reguiatioo of c-myc and cyclin Dl, which normally 
promote proliferation. Once these cells became diffcrenci- 
ated and quiescent, re-expression of c-myc resulted in 
apoptosis. By contrast, high expression levels of c-myc 
and cyclin Dl in proliferating mammary cells were not 
accompanied by apoptosis [31]. Furthermore, overexpres- 
sion of pz1 WAF-l/CIP-I, a cell-cycle-arrest molecule that is 
highly expressed during differentiation, led to apoptosis 
when overexpressed in the proliferating mammary cells 
[31]. These findings couple the regulation of cell survival 
by the ECM intimately to cell-cycle control, and suggest 
that introduction of signals that are in conflict with those 
mediated through the integrins may result in apoptosis. 
Not surprisingly, cell-cycle progression is also controlled 
by cell adhesion, linked to adhesion-dependent cegula- 
tion of cyclin A and the cyclin-dependent kinase (cdk)- 
inhibitors p21wA”-1/cn’-1 and p27K1P-1 [32,33]. 
lntegrins and vascular cell survival 
Primary endothelial cells are anchorage-dependent and 
undergo apoptosis when denied integrin-mediated attach- 
ment, indicating that integrins regulate endothelial cell sur- 
vival in G-o 125,341. However, these studies do not address 
integrin specificity or whether these events take place in a 
complex three dimensional extracellular matrix cnviron- 
menc in viva. Blocking inregrin CI,& results in the induc- 
tion of apoptosis among proliferating vascular cells as 
described above [13]. Specific antibody or cyclic pepdde 
antagonists of CI$~ administered systemically during angio- 
genesis on the chick CAM also induce endothelial cell p53- 
dependent DNA binding activity, whereas antibodies to 
integrin B, have no effect on p53 activity or apoptosis 
[13,35]. This induction of p53 activity is accompanied by 
an increased expression of the p53-inducible cell-cycle 
inhibitor p21WA~~1~CrP-‘. Furthermore, using immobilized 
anti-integrin antibodies as agonists of integin function ila 
vitro, it has been shown that ligation .of cuhured human 
endothelial cell c&, but not other integrins, is sufficient to 
suppress ~53 activity without changing p53 protein expres- 
sion. The reduced ~53 activity is accompanied by a sharp 
decrease in p21WAF-“““‘-’ protein levels, demonstrating 
that the ligation state of integrin a,& directly regulates 
both of the cell cycle inhibitors ~$3 and pZ1wArs-t~cn’-l 
[35]. Ligation of CX,& also enhanced Bcl-2 expression while 
decreasing that of Bax. The resulting increase in the Bcl- 
2:Bax ratio has been shown previously to promote cell sur- 
vival [28]. Thus, ligand binding by endotheliat cell integrin 
LY& suppresses apoptosis and conflicting growth-arrest 
signals, thereby facilitating the proliferation and maturation 
of new blood vessels during angiogcnesis. 
It is not clear whether activation of the cell-cycle 
inhibitors ~53 and p21WAF-“C~1P-1 by (Y,B~ antagonists 
is the direct cause of apopcopsis during angiogenesis. 
However, integrin CY& mediates adhesion to proteins 
that typically comprise a provisional matrix, such as prote- 
olysed collagen, vitronectin, fibronectin and fibrinogen. 
As these matrix components promote cell proliferation 
129,303, it might be expected that l&and binding to CX,B~ 
would in turn suppress the activity of molecules such as 
p53 .snd p21w&f/cIp-~, which otherwise could inhibit 
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cell-cycle progression and induce apoptosis [31,35,36]. 
This suggests a model..,in which integrin-exrracellular 
matrix interactions are ne&sary to coardinate the activity 
of both cell-cycle promotors and inhibitors during angio- 
genesis (Fig. 2). Thus, during endotheliai cell prolifera- 
tion, an interaction between (yyp3 and the provisional 
ECM would suppress conflicting growth-arrest signals, 
such as ~53 and ~21 LvAF-l~CIP-t [35,36]. However, to 
secure vascular cell survival during differentiation, the 
basement membrane would coordinately downregulate 
molecules that promote cell-cycle progression when cell- 
cycle inhibitors become activated. This may avoid a 
Figure 2 
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Hypothetical model for the role of integrin a,& in angiogenesis. 
Angio-genie stimulus by bFGF induces expression of integrin o,ps and 
causes cells to invade the surrounding ECM and to enter the cell 
cycle. If ligation of ‘Y,& is blocked, endothelial cell p53 activity is 
induced, accompanied by increased ~21 wAF-l/cIp-l expression, a 
decrease in the bcl-Wbax ratio and apoptosis of proliferating vascular 
cells [I 3,321. This suggests a model where the interaction between 
integrins and the extracellular matrix regulates proliferation and 
survivat. To facilitate cell prolifer-ation and survival, the interaction 
between DL$~ and the provisional ECM suppresses potentially 
conflicting growth arrest signals by btocking p53 activity.and 
p21w*F-l’clp-l expression [32]. This enables vessel maturation 
associated with the formation of an intact basement membrane, 
leading to final endothetial differentiation and lumen formation. 
potential conflict chaE otherwise would lead to apoptosis, 
as has been observed when c-myc is introduced into 
mammary epithelial cells that are allowed to differentiate 
on a basement membrane [31]. 
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